Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000359791 | SCV000344872 | uncertain significance | not provided | 2016-09-15 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000359791 | SCV001394610 | pathogenic | not provided | 2024-01-15 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 7 of the TPP1 gene. It does not directly change the encoded amino acid sequence of the TPP1 protein. RNA analysis indicates that this variant induces altered splicing and likely results in the gain of 3 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has been observed in individual(s) with neuronal ceroid lipofuscinosis in a family and has also been observed in unrelated affected individuals (PMID: 17959406, 23266810). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS7-10A>G. ClinVar contains an entry for this variant (Variation ID: 2649). Studies have shown that this variant results in the activation of a cryptic splice site in intron 7 (PMID: 17959406). For these reasons, this variant has been classified as Pathogenic. |
Mendelics | RCV000002768 | SCV002519894 | pathogenic | Neuronal ceroid lipofuscinosis 2 | 2022-05-04 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000002768 | SCV000022926 | pathogenic | Neuronal ceroid lipofuscinosis 2 | 2008-01-01 | no assertion criteria provided | literature only |